Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBK011 is a standardized, ready-to-use oral glucose solution developed by Chengdu Shibeikang Biomedical Technology for use in the Oral Glucose Tolerance Test (OGTT). Traditionally, the OGTT requires the manual dissolution of 75 grams of anhydrous glucose powder in water, a process that can be prone to variability in concentration and may cause patient discomfort or nausea. SBK011 is designed as a pre-formulated alternative to improve the consistency of the diagnostic challenge, enhance patient preference, and ensure safety. It is primarily utilized in clinical settings to evaluate glycemic response and insulin secretion for the diagnosis of impaired glucose tolerance and type 2 diabetes mellitus. Clinical evaluation, such as trial CTR20261733, has focused on comparing its diagnostic accuracy and tolerability against the traditional glucose powder method in healthy volunteers and individuals with impaired glucose tolerance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SBK011.